Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Apr 21, 2018 11:53pm
209 Views
Post# 27922711

RE:RE:RE:RE:WOW ATE TARGET 1.40 !!!!

RE:RE:RE:RE:WOW ATE TARGET 1.40 !!!!Thanks for the extra info. I agree with you. The 30% seems high, I thought the Zack's number (12%?? 15%??) made more sense. On timelines I dont think approval(if we get there) can come before 2021 and you would hope they can get it completed before 2024. Maybe these are best seen as the low and high ends of a plausible range of an approval timeline. With money in their pocket I dont think Wallace will take his time, if you include NicOx he's been at this for the whole of this century :)

But as with many things for Antibe its all dependant on what the partnership deal looks like.

Bobwins wrote:

The analyst gave a 1 year price target of C$1.40 so it's not that unreasonable.  In the analysis there are pluses and minuses.  He used a royalty rate of up to 30% so income is much higher after commercialization BUT he uses 2024 as the approval and commercialization date.  This is far later than Zack's date of 2021.   In order for Antibe to get that high a royalty rate, they would probably have to finance the phase III trials themselves.  Given the company's preference for finding a phase III partner to finance the trials, this seems odd.  
 



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities